Orbis Health Solutions (United States)

Recent papers from Orbis Health Solutions (United States)

1. Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIa Trial2024
2. Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trialCancer Treatment and Research Communications · 2024
3. Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaMelanoma Research · 2021
4. Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysisCancer Medicine · 2021
5. Tumor Lysate Particle Loaded Dendritic Cell Vaccine: Preclinical Testing of a Novel Personalized Cancer VaccineImmunotherapy · 2018
6. A biotin-streptavidin-biotin bridge dramatically enhances cell fusionOncology Letters · 2014
7. An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activationInternational Journal of Oncology · 2012